Pluri (PLUR) Common Equity (2011 - 2025)
Pluri (PLUR) posted quarterly Common Equity of -$9.2 million for Q4 2025, down 215.84% year-over-year from $8.0 million in Q4 2024, and down 63.15% quarter-over-quarter from -$5.6 million in Q3 2025.
Pluri (PLUR) Common Equity (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Common Equity for 15 consecutive years, with -$9.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 215.84% year-over-year to -$9.2 million; the TTM figure through Dec 2025 stood at -$9.2 million (down 215.84% YoY), while the FY2025 annual figure was -$865000.0, down 115.97% from the prior year.
- Common Equity retreated to -$9.2 million in Q4 2025 per PLUR's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Common Equity topped out at $68.1 million in Q1 2021 and bottomed at -$9.2 million in Q4 2025.
- Historically, Common Equity has averaged $18.8 million across 5 years, with a median of $13.2 million in 2023.
- Annual changes were most pronounced in 2021 — Common Equity jumped 380.88% — and 2025, when it plunged 8863.49%.
- Pluri's Common Equity stood at $39.8 million in 2021, then tumbled by 37.33% to $25.0 million in 2022, then plunged by 73.5% to $6.6 million in 2023, then slumped by 144.08% to -$2.9 million in 2024, then sank by 215.84% to -$9.2 million in 2025.
- Business Quant data shows PLUR's Common Equity at -$9.2 million in Q4 2025, -$5.6 million in Q3 2025, and -$865000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Pluri | 16.11 Mn | 3.63 Mn | 86,000.00 | -14.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.21 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -865,000.00 |
| Mar 31, 2025 | -4.47 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -63,000.00 |
| Jun 30, 2024 | 5.42 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 6.62 Mn |
| Sep 30, 2023 | 11.04 Mn |
| Jun 30, 2023 | 15.30 Mn |
| Mar 31, 2023 | 20.88 Mn |
| Dec 31, 2022 | 24.97 Mn |
| Sep 30, 2022 | 26.90 Mn |
| Jun 30, 2022 | 32.19 Mn |
| Mar 31, 2022 | 40.14 Mn |
| Dec 31, 2021 | 39.84 Mn |
| Sep 30, 2021 | 48.91 Mn |
| Jun 30, 2021 | 57.15 Mn |
| Mar 31, 2021 | 68.14 Mn |